Tag: board

Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGAP®-Verify discovery platform

At the Annual General Meeting of Fingerprint Cards AB (publ) (“FPC” or the “Company”) held on June 24, 2025, a resolution was passed to carry out a reverse share split, whereby two thousand (2,000) existing shares will be consolidated into one (1) new share (reverse split 1:2,000). The AGM also resolved to authorize the Board of Directors to determine the record date for the reverse split.

VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) -- DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB: DMGGF) (FRANKFURT: 6AX) ("DMG" or the "Company"), a vertically integrated blockchain and data center technology company, today announces its preliminary operational results for June 2025:

MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it has entered into a binding arrangement agreement with CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”), a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products, whereby the Purchaser will acquire all the issued and outstanding common shares of the Company for US$3.01 per share in cash plus one contingent value right (“CVR”) per share for additional aggregate cash payments of up to US$1.19 per CVR if certain milestones as described below are achieved (the “Transaction”). The total Transaction consideration, assuming full payment of the CVRs, is US$254 million.

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against AppLovin Corporation (NASDAQ:APP) on behalf of long-term stockholders following a class action complaint that was filed against AppLovin on March 5, 2025 with a Class Period from May 10, 2023 to March 26, 2025.. Our investigation concerns whether the board of directors of AppLovin have breached their fiduciary duties to the company.